CAJ | 학술논문

目的：探讨125I放射性粒子植入及肝动脉灌注化疗治疗肝癌TACE术后残存病灶的临床价值。方法选取2008年1月～2012年1月总共63例肝癌行TACE治疗后残留病灶的患者纳入研究。随机分成2组：33例行125 I放射性粒子植入治疗，为A组，30例行肝动脉灌注吉西他滨+奥沙利铂治疗，为B组。分别评价2组患者的临床疗效及毒副反应。结果125 I放射性粒子植入治疗33例患者，总有效率81.8％(27/33)，中位生存期18.5个月。肝动脉灌注吉西他滨+奥沙利铂治疗30例，总有效率44.33%(13/30)，中位生存期13个月。125 I放射性粒子植入组有效率及中位生存期明显高于吉西他滨+奥沙利铂组，差异有统计学意义(P＜0.05)。结论125 I放射性粒子植入治疗肝癌TACE术后残存病灶是一种安全、有效的治疗方法。
목적：탐토125I방사성입자식입급간동맥관주화료치료간암TACE술후잔존병조적림상개치。방법선취2008년1월～2012년1월총공63례간암행TACE치료후잔류병조적환자납입연구。수궤분성2조：33례행125 I방사성입자식입치료，위A조，30례행간동맥관주길서타빈+오사리박치료，위B조。분별평개2조환자적림상료효급독부반응。결과125 I방사성입자식입치료33례환자，총유효솔81.8％(27/33)，중위생존기18.5개월。간동맥관주길서타빈+오사리박치료30례，총유효솔44.33%(13/30)，중위생존기13개월。125 I방사성입자식입조유효솔급중위생존기명현고우길서타빈+오사리박조，차이유통계학의의(P＜0.05)。결론125 I방사성입자식입치료간암TACE술후잔존병조시일충안전、유효적치료방법。
Objective To evaluate the clinical efficacy of125I seeds implantation and transarterial infusion in the treatment of residual hepatocellular carcinoma after transcatheter arterial chemocebolization.Methods From January 2008 to January 2012. Retrospectively analyzed clinical datas of 63 patients were randomly divided into two groups. 33 cases were treated with125I seeds (group A), 30 cases were treated with gemcitabine and oxaliplatin (group B). The efficacy and toxicity in the two groups were evaluated.Results In125I seeds group the total effcetive rate was 81.8%(27/33),the median survival times was 18.5 months. In gemcitabine and oxaliplatin group the total effcetive rate was 43.33%(13/30), the median survival times was 13 months. The total effcetive rate and median survival in125I seeds group were significantly higher and longer than those in gemcitabine and oxaliplatin group (P<0.05).Conclusion It is safe and effective that radioactive seeds125I was used for implantation in treating residual hepatocellular carcinoma after TACE.